Literature DB >> 2495724

Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia.

D M Knowles1.   

Abstract

The author reviews the immunophenotypic profiles displayed by the major clinicopathologic categories of T cell neoplasia, the immunophenotypic criteria useful in the immunodiagnosis of T cell neoplasia, and the contributions made by antigen receptor gene rearrangement analysis to the understanding of T cell neoplasia. Neoplasms belonging to distinct clinicopathologic categories of T cell neoplasia often exhibit characteristic immunophenotypic profiles. Approximately 80% of lymphoblastic lymphomas and 20% of acute lymphoblastic leukemias express phenotypes consistent with prethymic and intrathymic stages of T cell differentiation, including intranuclear terminal deoxynucleotidyl transferase. Cutaneous T cell lymphomas of mycosis fungoides type usually express pan-T cell antigens CD2, CD5, and CD3, often lack the pan-T cell antigen CD7, and usually express the mature, peripheral helper subset phenotype, CD4+ CD8-. Cutaneous T cell lymphomas of nonmycosis fungoides type and peripheral T cell lymphomas often lack one or more pan-T cell antigens and, in addition, occasionally express the anomalous CD4+ CD8+ or CD4- CD8- phenotypes. T gamma-lymphoproliferative disease is divisable into two broad categories: those cases that are CD3 antigen positive and exhibit clonal T cell receptor beta chain (TCR-beta) gene rearrangements and those cases that are CD3 antigen negative and exhibit the TCR-beta gene germline configuration. Human T cell lymphotropic virus-I (HTLV-I) associated Japanese, Carribean, and sporadic adult T cell leukemia/lymphomas usually express pan-T cell antigens, the CD4+ CD8- phenotype, and various T cell-associated activation antigens, including the interleukin-2 receptor (CD25). Immunophenotypic criteria useful in the immunodiagnosis of T cell neoplasia include, in increasing order of utility, T cell predominance, T cell subset antigen restriction, anomalous T cell subset antigen expression, and deletion of one or more pan-T cell antigens. Only in exceptional circumstances do normal, non-neoplastic T cell populations express the CD4- CD8- or the CD4+ CD8+ phenotype and/or lack one or more pan-T cell antigens. T cell receptor beta chain gene rearrangement analysis represents an accurate, objective, and sensitive molecular genetic marker of T cell lineage and clonality that allows discrimination among non-T cell, polyclonal T cell and monoclonal T cell populations. Non-T cells exhibit the TCR-beta gene germline configuration.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2495724      PMCID: PMC1879785     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  194 in total

1.  A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies.

Authors:  M Link; R Warnke; J Finlay; M Amylon; R Miller; J Dilley; R Levy
Journal:  Blood       Date:  1983-10       Impact factor: 22.113

2.  Monoclonal antibody OKT-9 recognizes the receptor for transferrin on human acute lymphocytic leukemia cells.

Authors:  J W Goding; G F Burns
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

3.  Characterization of Langerhans cells by the use of monoclonal antibodies.

Authors:  G F Murphy; A K Bhan; S Sato; T J Harrist; M C Mihm
Journal:  Lab Invest       Date:  1981-11       Impact factor: 5.662

4.  Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.

Authors:  J Ritz; L M Nadler; A K Bhan; J Notis-McConarty; J M Pesando; S F Schlossman
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

5.  Predictability of immunologic phenotype by morphologic criteria in diffuse aggressive non-Hodgkin's lymphomas.

Authors:  E S Jaffe; J A Strauchen; C W Berard
Journal:  Am J Clin Pathol       Date:  1982-01       Impact factor: 2.493

6.  Diversity of immunological phenotypes of lymphoblastic lymphoma.

Authors:  J Cossman; T M Chused; R I Fisher; I Magrath; F Bollum; E S Jaffe
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

7.  Node-based T cell lymphoma. The clinical, immunological and morphological spectrum.

Authors:  A S Leong; B M Dale; S H Liew; R E Sage; I J Forbes
Journal:  Pathology       Date:  1981-01       Impact factor: 5.306

8.  Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma.

Authors:  A Bernard; L Boumsell; E L Reinherz; L M Nadler; J Ritz; H Coppin; Y Richard; F Valensi; J Dausset; G Flandrin; J Lemerle; S F Schlossman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

9.  Surface phenotype of Japanese adult T-cell leukemia cells characterized by monoclonal antibodies.

Authors:  T Hattori; T Uchiyama; T Toibana; K Takatsuki; H Uchino
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

10.  Lymphoblastic lymphoma: a clinicopathologic study of 95 patients.

Authors:  B N Nathwani; L W Diamond; C D Winberg; H Kim; R M Bearman; J H Glick; S E Jones; R A Gams; N I Nissen; H Rappaport
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

View more
  17 in total

1.  Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis.

Authors:  S Signoretti; M Murphy; M G Cangi; P Puddu; M E Kadin; M Loda
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

2.  An overview of ocular adnexal lymphoid tumors.

Authors:  F A Jakobiec; D M Knowles
Journal:  Trans Am Ophthalmol Soc       Date:  1989

3.  Gadolinium enhanced magnetic resonance imaging in the diagnosis of anterior visual pathway meningiomas.

Authors:  M G Alper; J L Sherman
Journal:  Trans Am Ophthalmol Soc       Date:  1989

4.  Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death.

Authors:  Paula V Cabrera; Maho Amano; Junya Mitoma; Jessica Chan; Jonathan Said; Minoru Fukuda; Linda G Baum
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

5.  Computer assisted selection and assessment of antibodies in the diagnosis of lymphomas.

Authors:  P J Harkin; S A Kelly; A S Jack
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

6.  Analysis of T cell receptor-gamma gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products. Correlation with tumor-specific sequences.

Authors:  T C Greiner; M Raffeld; C Lutz; F Dick; E S Jaffe
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

7.  A case of primary central nervous system lymphoma (PCNSL) of putative T-cell lineage.

Authors:  W Paulus; K A Jellinger
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings.

Authors:  Yasushi Onishi; Yoshihiro Matsuno; Ukihide Tateishi; Akiko Miyagi Maeshima; Masahiko Kusumoto; Takashi Terauchi; Shigeru Kusumoto; Naohiro Sekiguchi; Kazuki Tanimoto; Takashi Watanabe; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

9.  Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth.

Authors:  H Merz; A Fliedner; K Orscheschek; T Binder; W Sebald; H K Müller-Hermelink; A C Feller
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

10.  Allotype distribution of human T cell receptor beta and gamma chain genes in Caucasians, Asians and Australian aborigines: relevance to chronic hepatitis B.

Authors:  P Soeharso; K M Summers; W G Cooksley
Journal:  Hum Genet       Date:  1992-04       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.